Researches Index A to Z
Filter:
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Background During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to...
More
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
BACKGROUND Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2...
More
Combination Therapy with Metformin plus Gliclazide in Patients with Type 2 Diabetes
Type 2 diabetes is a chronic, degenerative disease, which requires management of the symptoms via lifestyle modification and anti-diabetic pharmacotherapies. If glycaemic targets are not maintained, patients can often require the addition of a second...
More
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
BACKGROUND Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients...
More
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Abstract Empagliflozin/linagliptin (Glyxambi) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixeddose combination product that is approved in the USA as an adjunct to diet and exercise in adults...
More